VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $750,000 | -24.0% | 68,000 | 0.0% | 0.13% | -26.2% |
| Q4 2016 | $987,000 | -40.9% | 68,000 | 0.0% | 0.17% | -42.5% |
| Q3 2016 | $1,669,000 | +21.8% | 68,000 | 0.0% | 0.30% | +17.3% |
| Q2 2016 | $1,370,000 | +349.2% | 68,000 | +2166.7% | 0.26% | +347.4% |
| Q4 2015 | $305,000 | -44.8% | 3,000 | -3.2% | 0.06% | -47.7% |
| Q3 2015 | $553,000 | -19.7% | 3,100 | 0.0% | 0.11% | -5.2% |
| Q2 2015 | $689,000 | +11.9% | 3,100 | 0.0% | 0.12% | +7.5% |
| Q1 2015 | $616,000 | +43.6% | 3,100 | +3.3% | 0.11% | +98.1% |
| Q4 2014 | $429,000 | +8.9% | 3,000 | 0.0% | 0.05% | 0.0% |
| Q3 2014 | $394,000 | +4.2% | 3,000 | 0.0% | 0.05% | -25.0% |
| Q2 2014 | $378,000 | -4.3% | 3,000 | 0.0% | 0.07% | -12.2% |
| Q1 2014 | $395,000 | +12.2% | 3,000 | 0.0% | 0.08% | +331.6% |
| Q4 2013 | $352,000 | +12.5% | 3,000 | 0.0% | 0.02% | -73.6% |
| Q3 2013 | $313,000 | +21.3% | 3,000 | 0.0% | 0.07% | -4.0% |
| Q2 2013 | $258,000 | – | 3,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,106,379 | $55,398,000 | 31.67% |
| Claren Road Asset Management, LLC | 80,000 | $2,820,000 | 24.27% |
| Okumus Fund Management Ltd. | 3,722,464 | $97,901,000 | 15.82% |
| Wingspan Investment Management, LP | 852,900 | $22,431,000 | 12.66% |
| FARLEY CAPITAL L.P. | 307,458 | $8,086,000 | 11.46% |
| Chou Associates Management | 976,843 | $25,725,000 | 8.35% |
| Wingspan Investment Management, LP | 550,700 | $14,483,000 | 8.17% |
| HAP Trading, LLC | 4,043,900 | $109,610,000 | 8.00% |
| LeVasseur Capital Partners LLC | 128,269 | $3,373,000 | 6.97% |
| Pershing Square Capital Management | 21,591,122 | $567,847,000 | 6.41% |